Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KOOL NYSE:PLX NASDAQ:SKYE NASDAQ:THMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKOOLCesca Therapeutics$11.89-1.3%$2.78$2.10▼$7.00$28.74M1.07112,188 shs3,389 shsPLXProtalix BioTherapeutics$1.45-0.7%$1.50$0.82▼$3.10$115.43M-0.23864,151 shs357,101 shsSKYESkye Bioscience$3.41-4.5%$3.28$1.14▼$7.47$105.62M2.21453,869 shs274,297 shsTHMOThermoGenesis$0.00$0.00▼$0.30$1K1.195,150 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKOOLCesca Therapeutics-1.34%-2.06%+0.97%+13.60%+12.05%PLXProtalix BioTherapeutics0.00%-3.97%-6.15%-51.67%+34.26%SKYESkye Bioscience0.00%-12.79%-25.46%+51.69%-34.04%THMOThermoGenesis0.00%0.00%0.00%0.00%-99.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKOOLCesca TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.3979 of 5 stars3.53.00.00.00.60.01.9SKYESkye Bioscience1.4574 of 5 stars3.52.00.00.01.90.00.0THMOThermoGenesis0.2298 of 5 stars0.03.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKOOLCesca Therapeutics 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00934.48% UpsideSKYESkye Bioscience 3.00Buy$16.60386.80% UpsideTHMOThermoGenesis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KOOL, THMO, PLX, and SKYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKOOLCesca Therapeutics$9.67M2.97N/AN/A$3.11 per share3.82PLXProtalix BioTherapeutics$59.76M1.93$0.08 per share17.80$0.47 per share3.09SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ATHMOThermoGenesis$9.61M0.00N/AN/A($0.99) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKOOLCesca Therapeutics-$39.72M-$3.60N/A1,189.39N/A-98.84%-77.30%-37.75%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/ASKYESkye Bioscience-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/ATHMOThermoGenesis-$17.98M-$5.14N/AN/AN/AN/AN/AN/AN/ALatest KOOL, THMO, PLX, and SKYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKOOLCesca TherapeuticsN/A0.50%N/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ATHMOThermoGenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKOOLCesca Therapeutics0.501.520.91PLXProtalix BioTherapeuticsN/A1.981.27SKYESkye BioscienceN/A11.8511.85THMOThermoGenesisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKOOLCesca Therapeutics3.11%PLXProtalix BioTherapeutics16.53%SKYESkye Bioscience21.09%THMOThermoGenesis5.78%Insider OwnershipCompanyInsider OwnershipKOOLCesca Therapeutics68.90%PLXProtalix BioTherapeutics6.50%SKYESkye Bioscience4.50%THMOThermoGenesis78.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKOOLCesca Therapeutics532.42 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableSKYESkye Bioscience1130.98 million29.58 millionOptionableTHMOThermoGenesis407.95 million1.75 millionNot OptionableKOOL, THMO, PLX, and SKYE HeadlinesRecent News About These CompaniesTHMO | ThermoGenesis Holdings Inc. Annual Cash Flow Statement | MarketWatchJuly 29, 2025 | marketwatch.comThe Ice Water Hack: How Aqua Sculpt Boosts Thermogenesis for Fat LossMarch 10, 2025 | globenewswire.comIce Water Hack: How Aqua Sculpt Improves Thermogenesis for Weight LossFebruary 20, 2025 | globenewswire.comNorth American Morning Briefing: Stock Futures, -2-September 19, 2024 | morningstar.comMIs Thermogenesis Holdings Inc Stock (THMO) a Good Investment?August 8, 2024 | aaii.comAThermoGenesis Holdings (OTC:THMO) Stock Quotes, Forecast and News SummaryJuly 28, 2024 | benzinga.comThermoGenesis Holdings (OTC:THMO) Stock, Short Interest ReportJuly 28, 2024 | benzinga.comWhy Is ThermoGenesis (THMO) Stock Down 37% Today?June 12, 2024 | investorplace.comTHMO Stock Earnings: ThermoGenesis Holdings Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | investorplace.comThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The CornerFebruary 27, 2024 | finance.yahoo.comThermoGenesis Holdings, Inc.January 9, 2024 | thestreet.comThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and DatesDecember 16, 2023 | benzinga.comShareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time BeingDecember 8, 2023 | finance.yahoo.comThermoGenesis Holdings Recent Insider ActivityNovember 21, 2023 | benzinga.comThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 15, 2023 | finanznachrichten.deThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comThermoGenesis Q3 Earnings PreviewNovember 12, 2023 | msn.comHere's what Wall Street expects from ThermoGenesis's earnings reportNovember 12, 2023 | markets.businessinsider.comThermoGenesis Holdings Inc THMONovember 12, 2023 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOOL, THMO, PLX, and SKYE Company DescriptionsCesca Therapeutics NASDAQ:KOOLCesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.Protalix BioTherapeutics NYSE:PLX$1.45 -0.01 (-0.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.03%) As of 08/1/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Skye Bioscience NASDAQ:SKYE$3.41 -0.16 (-4.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.40 -0.01 (-0.29%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.ThermoGenesis NASDAQ:THMOThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
